SIMBA in Irritable Bowel Syndrome (IBS)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study is intended to characterize longitudinal changes in the small intestinal microbiome following rifaximin treatment in participants with Irritable Bowel Syndrome (IBS) over a 12 week period.
Epistemonikos ID: 8eb1a6d71a4600d7281b8b7c4deb02918840c699
First added on: Oct 21, 2026